Many factors come into that sell-off in the 2017 world of investing in these biotech companies. The actual data they released isn't a death sentence by any means, but the stock fluctuation will make it seem like that.
- Massive run-up due to almost-perfect market sentiment and a couple strong catalysts
- Hot sector of biotech with the opiod crisis, makes it ripe for over-exuberance on a drug that disrupts the opiod market
- Ease of access for the average investor these days to invest turns in to mass-panic at the very second the market sentiment changes, hence CARA.
NEMUS will benefit in the near future of this over-exuberance. 2nd Half 2017 and 2018 will be hot fire with biotech, cannabinoids, and more robinhood accounts getting created on the daily for small-time folk to jump in.
News 
Market Data 
Discover 
